Press Releases from Piramal | Healthcare (4 total)
Piramal Enterprises’Pharma Solution Division receives two coveted CMO Leadersh …
April 7,2014,Boston,USA:
Piramal Enterprises’ Pharma Solutions Division, a global pharmaceutical contract development and manufacturing organization(CDMO), has received CMO Leadership Awards 2013 in two categories–Quality and Reliability, at a prestigious ceremony at DCAT in NewY ork. Within the Reliability category, Piramal has been recognized as the most “Reliable”CMO among the 5CMO’s short listed for this award.
The CMO Leadership Awards are given by Life Science Leader based on the industry leading research conducted…
NeuraceqTM (florbetaben F18 injection) Data: an Emerging Science Topic at the Am …
Berlin/Boston/Mumbai, April 30, 2014 ‒
Piramal Imaging today announced that data from its beta-amyloid PET tracer NeuraceqTM clinical trial will be featured as part of Emerging Science sessions at the 66th American Academy of Neurology Annual Meeting at the Pennsylvania Convention Center Philadelphia, Penn.
A presentation by Marwan Sabbagh MD, FAAN, director of the Banner Sun Health Research Institute Research and Professor of Neurology at the University of Arizona, will focus…
CPPIB and Piramal Enterprises Limited announce a US$500m Strategic Alliance
For Residential Development Debt Financing in India; Appoint Indiareit as Advisor
Toronto, Canada/Mumbai, India (February 12th, 2014): CPPIB Credit Investments Inc., a wholly-owned subsidiary of Canada Pension Plan Investment Board (CPPIB), and Piramal Enterprises Limited (PEL), one of India’s largest diversified companies, announced today a strategic alliance for providing rupee debt financing to residential projects across India’s major urban centres. CPPIB and PEL have each initially committed US$250 million for…
Piramal’s healthcare vertical invests USD $2.5 million to further expand comme …
• Piramal | Healthcare was the first contract supplier of ADCs globally.
July 23, 2013, Grangemouth, Scotland, UK: Piramal’s Healthcare vertical today announced that it is to invest USD 2.5 million at its FDA approved Grangemouth, UK, site to upgrade one of its antibody drug conjugate (ADC) manufacturing suites, from clinical phase to commercial grade, in response to customer demand. The upgrade will give Piramal two commercial grade ADC suites…
